halofuginon
lactat
hl
regist
sever
countri
prevent
calf
cryptosporidiosi
compound
util
presenc
coinfect
enteropathogen
well
understood
perform
random
control
field
trial
efficaci
hl
prevent
natur
calf
cryptosporidiosi
presenc
coinfect
rotaviru
salmonella
typhimurium
newborn
calv
one
farm
sequenti
enrol
alloc
full
dose
n
half
dose
n
placebo
control
group
n
use
random
block
design
cryptosporidium
oocyst
fecal
specimen
collect
day
count
sever
diarrhea
assess
use
fecal
consist
score
solid
semisolid
liquid
oocyst
number
fecal
consist
score
statist
compar
group
nineti
one
percent
calv
shed
cryptosporidium
parvum
oocyst
trial
full
dose
group
longer
prepat
period
control
group
statist
differ
number
oocyst
identifi
group
control
effect
sex
breed
fecal
consist
score
mortal
rate
differ
group
result
indic
anticryptosporidium
activ
clinic
benefit
hl
limit
conclud
order
maxim
clinic
efficaci
hl
field
diagnost
effort
aim
rule
presenc
enteropathogen
cosmopolitan
protozoan
parasit
cryptosporidium
parvum
infect
human
rang
host
common
agent
calf
diarrhea
first
four
week
life
gulliksen
et
al
lanz
uhd
et
al
millemann
trotzwilliam
et
al
spectrum
sever
cryptosporidiosi
calv
vari
subclin
infect
sever
diarrhea
dehydr
fayer
et
al
klein
et
al
ohandley
et
al
typic
natur
experiment
infect
c
parvum
calv
prepat
period
day
follow
patent
period
character
bellshap
oocyst
excret
curv
number
fecal
oocyst
peak
rapidli
decreas
undetect
level
matter
day
fayer
et
al
grinberg
et
al
oocyst
number
high
oocyst
per
gram
fece
report
peak
excret
fayer
et
al
grinberg
et
al
wherea
infect
rate
high
report
calv
first
month
life
lower
infect
preval
consist
observ
wean
anim
bartel
et
al
brook
et
al
fayer
xiao
fayer
et
al
garber
et
al
newborn
calv
therefor
consid
major
amplifi
potenti
zoonot
c
parvum
natur
prevent
calf
cryptosporidiosi
relev
anim
human
health
perspect
hunter
thompson
kiang
et
al
smith
et
al
grinberg
et
al
xiao
feng
zhou
et
al
sever
featur
c
parvum
life
cycl
make
control
cryptosporidiosi
onfarm
extrem
difficult
achiev
mean
hygien
measur
alon
calv
excret
hundr
million
oocyst
naciri
et
al
grinberg
et
al
consid
high
probabl
infect
dose
low
oocyst
moor
et
al
infect
calf
could
produc
enough
oocyst
infect
thousand
new
anim
attempt
interrupt
transmiss
c
parvum
therefor
includ
immedi
isol
everi
infect
anim
rare
feasibl
commerci
farm
addit
c
parvum
oocyst
insensit
action
numer
disinfect
chen
et
al
quilez
et
al
excret
sporul
fulli
infecti
smith
et
al
requir
daili
clean
remov
therefor
absenc
effect
immun
agent
pharmacolog
control
strategi
remain
central
prevent
cryptosporidiosi
calv
number
compound
halofuginon
lactat
hl
lefay
et
al
jarvi
et
al
klein
de
wael
et
al
trotzwilliam
et
al
paromomycin
sulphat
fayer
elli
grinberg
et
al
nitazoxanid
ollivett
et
al
schnyder
et
al
decoquin
moor
et
al
lallemond
et
al
test
prevent
cryptosporidiosi
calv
variabl
result
hl
synthet
deriv
quinazolinon
alkaloid
cryptosporidiostat
activ
mode
action
poorli
character
natur
experiment
infect
calv
oral
administr
gkg
hl
seven
consecut
day
first
day
life
delay
onset
oocyst
shed
reduc
number
oocyst
excret
lower
sever
diarrhea
joachim
et
al
klein
lefay
et
al
trotzwilliam
et
al
villacorta
et
al
formul
contain
hl
halocur
intervet
ltd
republ
ireland
current
prescript
drug
regist
prevent
cryptosporidiosi
calv
sever
countri
use
hl
number
limit
includ
substanti
market
price
narrow
therapeut
index
toxic
observ
approxim
twice
recommend
dose
villacorta
et
al
naciri
et
al
trotzwilliam
et
al
http
wwwmsdanimalhealthco
ukproduct
product
datasheetaspx
access
juli
remark
notwithstand
frequent
occurr
coinfect
cryptosporidium
enteropathogen
field
de
la
fuent
et
al
naciri
et
al
tzipori
et
al
util
hl
presenc
coinfect
well
understood
inde
except
klein
lefay
et
al
anticryptosporidium
efficaci
studi
hl
analyz
took
account
presenc
coinfect
coinfect
might
modifi
anticryptosporidium
effect
hl
differ
way
increas
fluid
content
intestin
motil
determin
presenc
coinfect
pathogen
may
reduc
activ
hl
dilut
reduc
transit
time
drug
intestin
tract
furthermor
enter
infect
rotaviru
agent
may
caus
exfoli
infect
cell
alter
intestin
cellular
function
ramig
potenti
increas
toxic
hl
via
system
absorpt
motiv
need
data
util
hl
presenc
coinfect
pathogen
perform
random
control
field
trial
anticryptosporidium
prevent
efficaci
compound
calv
new
zealand
farm
enzoot
infect
c
parvum
bovin
rotaviru
salmonella
typhimurium
studi
perform
juli
octob
farm
situat
taranaki
district
new
zealand
consent
studi
obtain
farmer
use
anim
approv
anim
ethic
committe
massey
univers
farm
manag
season
spring
calv
dairi
herd
approxim
milk
cow
smaller
herd
beef
cattl
recruit
follow
postmortem
investig
perform
march
two
calv
conduct
one
author
ag
indic
presenc
cryptosporidium
oocyst
fece
two
calv
salmonella
rule
cultur
rotaviru
coronaviru
antigen
elisa
sequenc
analysi
cryptosporidium
rrna
gene
subsequ
confirm
c
parvum
anim
notwithstand
microbiolog
result
perform
march
bovin
rotaviru
salmonella
spp
subsequ
identifi
multipl
enrol
calv
studi
see
studi
random
control
field
trial
see
random
procedur
commerci
product
halocur
intervet
ltd
republ
ireland
regist
new
zealand
prevent
treatment
cryptosporidiosi
calv
use
test
efficaci
hl
product
recommend
prevent
dose
mg
ml
calv
weigh
kg
mg
ml
calv
weigh
kg
seven
consecut
day
birth
initi
aim
assess
prevent
efficaci
half
recommend
dose
hl
compar
full
dose
treatment
follow
treatment
group
establish
group
full
dose
regim
n
calv
treat
oral
ml
halocur
group
half
dose
regim
n
calv
treat
ml
halocur
group
placebo
control
group
n
calv
treat
ml
water
deliv
use
product
dispens
group
size
estim
use
power
analysi
detect
differ
mean
use
pass
softwar
ncss
kaysvil
ut
assumpt
calcul
log
transform
mean
number
oocyst
per
gram
fece
full
dose
untreatedcontrol
group
peak
shed
common
standard
deviat
mean
estim
previous
publish
studi
efficaci
paromomycin
sulphat
grinberg
et
al
group
size
calv
per
group
achiev
power
reject
null
hypothesi
group
mean
thu
assum
conserv
infect
rate
calv
per
group
requir
manag
enrol
calv
follow
routin
procedur
use
farm
briefli
newborn
calv
left
calv
paddock
h
birth
commonli
done
new
zealand
pasturebas
farm
allow
colostrum
intak
directli
dam
newborn
transfer
larg
shed
alloc
pen
newborn
calv
capac
calv
calv
left
pen
day
transfer
new
pen
order
creat
space
new
calv
first
pen
subsequ
calv
progress
new
pen
often
adjac
contain
anim
age
group
everi
day
wean
alloc
calv
pen
done
caretak
awar
natur
treatment
given
calf
effect
creat
commingl
pen
design
adjac
pen
separ
slat
wooden
fenc
sawdust
use
bed
materi
feed
regimen
includ
administr
complet
commerci
milk
replac
first
two
week
use
tank
multipl
nippl
follow
feed
ad
libitum
use
automat
feeder
wean
roughag
avail
second
week
life
routin
vaccin
prevent
treatment
supplement
administ
calv
studi
howev
inappet
calv
could
tubef
sever
diarrheic
calv
treat
oral
electrolyt
andor
treatment
caretak
sever
sick
calv
transfer
isol
shed
studi
protocol
stipul
tube
fed
calv
could
continu
studi
anim
treat
farmer
mean
transfer
isol
pen
remov
newborn
calv
sequenti
enrol
morn
arriv
calv
area
rear
shed
calf
born
farm
elig
enrol
provid
congenit
patholog
condit
identifi
day
enrol
day
calv
identifi
ear
neck
tag
number
given
sequenti
number
alloc
one
three
treatment
group
alloc
calv
treatment
group
done
use
random
block
design
block
three
one
calf
per
group
use
random
list
prepar
advanc
fourth
calf
present
investig
block
three
systemat
left
unenrol
continu
normal
life
cycl
farm
treatment
administ
morn
use
commerci
product
see
fecal
specimen
collect
time
treatment
rectum
calf
use
dispos
glove
day
time
collect
specimen
score
accord
consist
solid
specimen
conserv
origin
shape
semisolid
specimen
spread
across
bottom
contain
liquid
liquid
specimen
specimen
transport
ice
massey
univers
kept
refriger
analyz
decemb
april
describ
fecal
specimen
analyz
quantit
method
estim
number
cryptosporidium
oocyst
present
briefli
mix
specimen
spatula
g
fece
suspend
ml
tap
water
strain
tea
siev
filtrat
centrifug
g
min
sediment
resuspend
ml
normal
salin
l
aliquot
suspens
deposit
drop
slide
use
micropipett
airdri
fix
methanol
fix
drop
stain
use
commerci
immunofluoresec
antigiardia
cryptosporidium
monoclon
antibodi
aquaglo
gc
direct
comprehens
kit
waterborn
inc
new
orlean
usa
accord
manufactur
instruct
applegreen
fluoresc
oocyst
present
entir
area
stain
drop
count
use
fluoresc
microscop
use
excit
wavelength
nm
magnif
len
total
number
oocyst
ton
slide
use
statist
analysi
see
sampl
contain
oocyst
difficult
count
reprocess
dilut
fecal
suspens
water
follow
stain
l
drop
ton
present
redilut
specimen
estim
multipli
result
avail
fecal
materi
insuffici
count
direct
fecal
smear
stain
qualit
result
presenceabs
oocyst
obtain
qualit
result
could
use
statist
comparison
number
oocyst
treatment
group
use
comparison
proport
cryptosporidiumposit
neg
specimen
march
dna
three
cryptosporidiumposit
specimen
treatment
group
extract
store
fece
use
dna
extract
kit
qiaamp
dna
stool
mini
kit
qiagen
hilden
gmbh
cryptosporidium
parasit
identifi
mean
pcrsequenc
rrna
gene
primer
aaa
ctg
cga
atg
gct
forward
ttt
cct
tcg
aaa
cag
revers
learmonth
et
al
amplif
perform
l
contain
l
x
pcr
buffer
l
dntp
mm
l
mgcl
mm
l
nonacetyl
bovin
serum
albumin
mgml
new
england
biolab
usa
picomol
primer
l
platinum
taq
dna
polymeras
mgml
invitrogen
corpor
carlsbad
ca
usa
pcr
amplif
carri
thermocycl
sensoquest
goettingen
germani
initi
denatur
c
min
follow
cycl
c
c
c
pcr
product
purifi
use
inhous
ethanol
purif
protocol
bidirect
sequenc
intern
segment
amplicon
perform
use
primer
forward
ccaatctctagttg
revers
forward
revers
sequenc
align
edit
manual
use
geneiou
softwar
version
biomatt
ltd
http
wwwgeneiou
com
distal
proxim
segment
could
verifi
trim
result
edit
sequenc
align
sequenc
deposit
genbank
use
align
algorithm
blast
http
blastncbinlmnihgovblastcgi
access
april
addit
analysi
cryptosporidium
fecal
specimen
taken
haphazardli
three
treatment
group
analyz
presenc
rotaviru
coronaviru
enterotoxigen
escherichia
coli
salmonella
spp
analysi
rotaviru
coronaviru
e
coli
perform
commerci
diagnost
laboratori
use
antigenelisa
institut
pourquier
montpelli
franc
analysi
salmonella
includ
parallel
inocul
fecal
materi
tetrathion
rappaportvassiliadi
soy
pepton
rv
broth
incub
h
c
c
respect
follow
subcultur
onto
xylos
lactos
deoxychol
agar
plate
incub
coloni
consist
salmonella
subcultur
triplesugar
iron
agar
slope
tsi
llysin
decarboxylas
broth
lysineposit
bacteria
exhibit
tsi
pattern
consist
salmonella
subject
salmonella
polyo
slide
agglutin
use
commerci
antiserum
institut
und
gmbh
berlin
berlin
germani
agglutin
isol
sent
salmonella
refer
laboratori
institut
environment
scienc
research
porirua
new
zealand
serotyp
parasitolog
clinic
effect
three
treatment
statist
compar
parasitolog
effect
analyz
compar
ton
group
use
analysi
varianc
repeat
measur
rmanova
implement
proc
mix
procedur
sa
statist
analysi
system
sa
institut
cari
nc
usa
ton
logtransform
log
ton
analyz
use
mix
model
first
model
model
includ
fix
effect
treatment
variabl
treatment
group
day
sampl
repeat
factor
variabl
sampl
day
interact
treatment
group
sampl
day
model
includ
fix
effect
model
plu
fix
effect
sex
calv
model
includ
factor
model
plu
effect
breed
calv
covari
variabl
breed
friesian
calf
nonfriesian
calf
fix
effect
variabl
breed
includ
class
due
unbalanc
design
deriv
uneven
distribut
breed
across
treatment
final
model
similar
model
includ
data
obtain
nonfreisian
calv
effect
remov
variabl
due
breed
model
includ
random
effect
calf
account
withincalf
variabl
use
akaik
inform
criterion
unstructur
error
structur
determin
appropri
residu
covari
structur
repeat
measur
time
within
anim
final
parasitolog
efficaci
also
assess
compar
declin
proport
parasitolog
neg
calv
function
time
three
group
use
nonparametr
kaplanmei
method
km
kaplan
meier
also
case
analysi
repeat
omit
data
nonfriesian
calv
km
analysi
implement
use
code
avail
r
terri
therneau
packag
surviv
analysi
r
packag
version
clinic
effect
treatment
assess
compar
fecal
consist
score
consid
ordin
data
group
sampl
day
use
nonparametr
kruskalw
test
test
perform
use
code
avail
r
kruskalw
http
statethzchrmanualrpatchedlibrarystat
htmlkruskaltesthtml
wilcoxon
http
stat
ethzch
rmanualrpatchedlibrarystatshtmlwilcoxontest
html
comparison
proport
interest
perform
use
twotail
fisher
exact
test
interpret
use
bonferroniadjust
critic
pvalu
multipl
test
final
exist
associ
fecal
consist
number
oocyst
shed
test
mean
logist
regress
use
log
ton
independ
variabl
presenceabs
liquid
specimen
fecal
score
outcom
variabl
analysi
perform
use
code
avail
r
http
wwwatsucla
edustatrdaelogithtm
r
packag
version
calv
enrol
within
h
birth
period
juli
august
total
calv
femal
statist
differ
proport
male
femal
among
treatment
group
friesian
angu
hereford
calv
one
jersey
angu
crossbr
calf
tabl
six
calv
haphazardli
select
enrol
weight
use
electron
scale
bodyweight
kg
mean
standard
deviat
indic
underoverdos
calv
unlik
occur
one
calf
die
day
enrol
calf
number
tabl
substitut
subsequ
calf
present
investig
calf
number
tabl
enrol
calv
remain
pen
studi
calf
withdrawn
due
concomit
treatment
thirti
eight
calv
follow
entir
observ
period
seven
die
differ
stage
studi
caus
death
defin
farmer
follow
two
calv
group
die
day
two
group
day
one
group
day
sever
diarrhea
two
calv
group
group
die
improp
tubefeed
possibl
milk
inhal
day
day
death
group
three
group
one
group
rate
statist
differ
tabl
fecal
specimen
could
retriev
analyz
tabl
total
calv
cryptosporidiumposit
immunofluoresc
stage
studi
two
calv
belong
group
abl
follow
entir
observ
period
remain
parasitolog
neg
throughout
studi
tabl
sequenc
analysi
gene
fecal
specimen
analyz
pcrsequenc
indic
presenc
c
parvum
case
specimen
analyz
enteropathogen
posit
rotaviru
salmonella
typhimurium
expect
calv
age
e
coli
specimen
identifi
although
analysi
giardia
spp
subject
studi
parasit
wide
consid
pathogen
calv
note
complet
giardia
cyst
observ
calv
immunofluoresc
number
cryptosporidiumnegativeposit
fecal
specimen
stratifi
treatment
group
sampl
day
day
similar
superscript
indic
comparison
proport
result
twotail
fisher
exact
test
p
less
bonferroniadjust
critic
probabl
sampl
day
group
full
dose
group
half
dose
group
placebocontrol
group
full
dose
group
half
dose
group
placebocontrol
day
day
day
day
day
calv
group
control
group
show
oocyst
shed
curv
typic
natur
cryptosporidiosi
major
anim
becom
parasitolog
posit
day
neg
day
tabl
group
start
shed
earlier
two
group
group
highest
mean
log
ton
observ
day
day
oocyst
observ
two
calv
tabl
contrast
group
peak
mean
log
ton
lower
occur
later
day
group
day
calv
group
shed
oocyst
two
group
howev
friesian
calv
consid
group
show
similar
oocyst
shed
curv
peak
group
day
comparison
crude
mean
log
ton
three
treatment
group
variou
sampl
day
report
fig
model
includ
effect
treatment
group
sampl
day
interact
term
indic
signific
differ
three
treatment
p
post
hoc
comparison
identifi
signific
differ
group
full
dose
group
control
group
log
ton
group
p
signific
differ
group
two
group
model
includ
also
fix
effect
sex
signific
treatment
group
preserv
p
signific
effect
sex
outcom
p
variabl
breed
introduc
covari
model
pvalu
effect
treatment
increas
p
covari
breed
also
signific
friesian
log
ton
nonfriesian
p
increas
pvalu
support
model
friesian
show
p
effect
treatment
model
produc
similar
pvalu
interact
treatment
day
remov
shown
order
crossvalid
result
compar
mean
log
ton
treatment
group
use
bivari
anova
sampl
day
separ
shown
consist
result
wherea
inclus
anim
result
statist
signific
differ
treatment
group
day
p
pvalu
friesian
calv
analyz
result
kaplanmei
test
indic
significantli
longer
prepat
period
group
compar
group
fact
calv
group
parasitolog
posit
day
wherea
three
calv
group
shed
oocyst
day
tabl
durat
prepat
period
group
intermedi
although
statist
differ
group
similar
result
observ
data
friesian
calv
analyz
fig
result
fisher
exact
test
show
day
proport
cryptosporidiumposit
calv
significantli
greater
group
group
twotail
fisher
exact
test
p
bonferroniadjust
critic
valu
hand
calv
group
two
calv
group
two
group
shed
oocyst
day
tabl
twenti
three
calv
pass
least
one
liquid
specimen
cours
studi
proport
liquid
specimen
day
rel
high
similar
three
treatment
group
tabl
result
kruskalw
wilcoxon
test
test
indic
signific
differ
p
fecal
consist
score
three
group
sampl
day
shown
except
one
signific
differ
group
group
day
proport
liquid
specimen
differ
group
tabl
result
persist
friesian
calv
includ
analysi
shown
associ
log
ton
presenc
liquid
specimen
logist
regress
p
halofuginon
lactat
regist
prevent
calf
cryptosporidiosi
sever
countri
compound
rel
narrow
therapeut
index
substanti
market
price
studi
initi
design
assess
efficaci
reduc
dosag
regim
hl
farm
infect
c
parvum
evid
presenc
coinfect
howev
identif
rotaviru
salmonella
typhimurium
multipl
calv
provid
opportun
collect
much
need
data
util
compound
presenc
common
coinfect
studi
design
predict
longer
prepat
period
decreas
number
oocyst
fecal
consist
score
full
dose
group
report
hl
absenc
document
coinfect
coinfect
rotaviru
salmonella
typhimurium
affect
abil
hl
full
dose
delay
onset
shed
wherea
calv
group
still
shed
oocyst
day
major
calv
control
group
alreadi
parasitolog
neg
day
tabl
prolong
prepat
period
coupl
statist
signific
differ
mean
log
ton
treatment
group
control
repeat
measur
sex
breed
calv
model
hypothes
hl
suppress
parasit
life
cycl
first
day
treatment
diarrhea
caus
pathogen
yet
overt
effect
prolong
prepat
period
group
convers
calv
group
pass
liquid
fece
day
earli
diarrhea
probabl
caus
coinfect
pathogen
could
shorten
intestin
transit
time
hl
last
day
treatment
effect
abolish
anticryptosporidium
effect
author
suggest
coinfect
multipl
agent
could
caus
sever
diarrhea
monoinfect
de
la
fuent
et
al
garcia
et
al
consequ
could
hypothes
suppress
one
organ
could
reduc
sever
tabl
number
liquid
fece
fecal
score
total
specimen
assess
stratifi
sampl
day
treatment
group
correspond
proport
bracket
sampl
day
asterisk
indic
twotail
fisher
exact
test
p
bonferroniadjust
critic
probabl
group
full
dose
group
half
dose
group
placebocontrol
diarrhea
studi
signific
differ
fecal
consist
score
treat
untreat
group
associ
ton
presenc
liquid
fece
found
logist
regress
furthermor
agreement
result
metaanalysi
literatur
et
al
mortal
rate
differ
group
therefor
result
allow
conclus
drawn
clinic
benefit
hl
presenc
coinfect
final
statist
signific
effect
breed
intens
oocyst
shed
observ
studi
intrigu
studi
previous
report
lower
cryptosporidium
infect
preval
beef
calv
dairi
calv
geurden
et
al
et
al
anticryptosporidium
activ
hl
fulli
preserv
use
drug
associ
clinic
benefit
presenc
enzoot
coinfect
rotaviru
salmonella
typhimurium
calv
diagnost
effort
therefor
aim
rule
presenc
common
enteropathogen
order
maxim
clinic
efficaci
hl
field
one
year
complet
studi
author
request
obtain
fund
msd
anim
health
new
zealand
new
distributor
halocur
perform
epidemiolog
studi
neonat
calf
diarrhea
dairi
farm
current
studi
perform
fund
request
compani
consult
prepar
manuscript
